Orforglipron Tracker.
The first oral GLP-1 pill without food and water restrictions — about 12.4% mean weight loss at 72 weeks in ATTAIN-1. Orforglipron is in clinical trials — here's what the published data says, and how GLP AI is ready for it.
Orforglipron is not FDA-approved. Investigational — Phase 3 trials complete/underway (ATTAIN, ACHIEVE programs). Not FDA-approved. Everything here comes from published trials, cited below — education, not medical advice. Products sold as "orforglipron" outside clinical trials are unregulated.
Orforglipron, from the published data.
Oral small-molecule GLP-1 receptor agonist — a non-peptide pill, so no food or water restrictions (unlike Rybelsus). Daily pill (in trials) — taken any time of day, no empty-stomach rule.
| Phase 3 result (obesity) | ATTAIN-1: ~12.4% mean weight loss at 72 weeks on the highest dose (36 mg daily) |
| Phase 3 result (type 2 diabetes) | ACHIEVE-1: A1C reductions of roughly 1.3–1.6% across doses |
| Why it matters | Small-molecule chemistry means no injection, no refrigeration, simpler manufacturing — and no Rybelsus-style empty-stomach ritual |
| Status | Eli Lilly has announced plans for regulatory submission; no FDA approval yet |
Sources: Phase 2 obesity trial — Wharton et al., NEJM 2023 · ATTAIN-1 Phase 3 trial record (ClinicalTrials.gov)
How Orforglipron differs from today's GLP-1s.
Rybelsus (oral semaglutide) is a peptide that survives the stomach only with a strict empty-stomach routine. Orforglipron is a small molecule — absorbed like a normal pill, taken any time. Its trial-average weight loss sits below injectable tirzepatide but removes the two biggest friction points: needles and the morning ritual.
GLP AI is orforglipron-ready.
Trial participants can track orforglipron in GLP AI today via custom medications — doses, meals with the 0–100 GLP-1 Meal Score, side effects, and weight on one timeline. When orforglipron launches, dose schedules and the medication level chart arrive with it, and your history carries over from whatever you track now.
Orforglipron — FAQs.
What is Orforglipron?+
Orforglipron is an investigational medication from Eli Lilly — oral small-molecule GLP-1 receptor agonist — a non-peptide pill, so no food or water restrictions (unlike Rybelsus). Investigational — Phase 3 trials complete/underway (ATTAIN, ACHIEVE programs). Not FDA-approved. This page is education from published trials, not medical advice.
Can I get Orforglipron now?+
Only through a clinical trial. Orforglipron is not FDA-approved, and products sold under its name outside trials are unregulated and potentially unsafe. Talk to your doctor about trial eligibility or approved alternatives.
Can GLP AI track Orforglipron?+
Yes — GLP AI supports custom medications, so trial participants can track doses, meals, side effects, and weight today. When Orforglipron launches, first-class support (dose schedules, level chart) arrives with it.
What should I use while waiting for Orforglipron?+
That's a conversation for your doctor — approved options include semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound). Whichever you're prescribed, GLP AI tracks it, and switching later keeps your history intact.
Is orforglipron approved by the FDA?+
Not yet. Phase 3 results (ATTAIN for obesity, ACHIEVE for type 2 diabetes) have been reported and Eli Lilly has announced regulatory submission plans, but there is no FDA approval as of mid-2026.
How is orforglipron different from Rybelsus?+
Both are oral GLP-1s, but Rybelsus is a peptide requiring an empty stomach, ≤4 oz of water, and a 30-minute wait. Orforglipron is a small molecule — no food or water restrictions, taken any time of day.
How much weight loss does orforglipron show?+
ATTAIN-1 reported roughly 12.4% mean weight loss at 72 weeks on 36 mg daily — below injectable tirzepatide's trial averages, but with pill convenience no injectable can match.
Go further with GLP AI.
Track it once. Understand it forever.
Start tracking today — your history carries into whatever comes next.